Back to top
more

Amarin (AMRN)

(Real Time Quote from BATS)

$14.27 USD

14.27
18,094

+0.14 (0.99%)

Updated Aug 19, 2026 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.94%
2Buy18.22%
3Hold10.27%
4Sell5.79%
5Strong Sell3.20%
S&P50011.55%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (146 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

by Zacks Equity Research

Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.

Zacks Equity Research

Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.

Zacks Equity Research

Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?

by Zacks Equity Research

Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect increasing patient days and admissions.

Zacks Equity Research

Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?

by Zacks Equity Research

Universal Health's (UHS) fourth-quarter results are likely to reflect improved performances from the Acute Care Hospital Services and Behavioral Health Care Services businesses.

Zacks Equity Research

Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.

Zacks Equity Research

Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?

by Zacks Equity Research

Select Medical's (SEM) fourth-quarter results are likely to reflect growing visits in Outpatient Rehabilitation and Concentra.

Zacks Equity Research

Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Altimmune's (ALT) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the development of its lead pipeline candidate, pemvidutide.

Kinjel Shah headshot

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

by Kinjel Shah

Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.

Zacks Equity Research

Are Medical Stocks Lagging Amarin (AMRN) This Year?

by Zacks Equity Research

Here is how Amarin (AMRN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Zacks Equity Research

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

by Zacks Equity Research

Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million. Stock gains.